GET DAILY SIGNALSDefinitive Healthcare (DH) Posts Q3 Revenue Drop of -9% but Beats on Adjusted Profitability
Key Takeaways
- Definitive Healthcare (DH) reported third-quarter 2026 revenue of $54.7 million, down about 9% from $60.0 million a year earlier.
- Adjusted EBITDA came in at $15.8 million, above the high end of the company's guidance range.
- Adjusted net income per diluted share was $0.06, topping management's $0.04–$0.05 outlook and the $0.04 consensus estimate.
- The GAAP net loss narrowed to roughly $5.4 million, a sharp improvement from the $17.8 million loss in the prior-year period.
- Operating cash flow and free cash flow softened year over year, reflecting continued pressure on the company's top line.
Earnings Context and Why It Matters
Definitive Healthcare (DH) provides healthcare commercial intelligence through subscription-based data and analytics that help life sciences, provider, and diversified organizations understand the U.S. healthcare ecosystem. Its results offer a useful signal for demand across healthcare software and data spending. The company has spent the past several quarters working through top-line contraction as customers trim budgets and shift toward shorter-duration contracts, even while management protects profitability through disciplined cost control. With revenue still declining in the high single digits, investors are watching closely to see whether improving retention and customer win-backs can translate into a return to growth, making each quarterly report a key checkpoint on the company's turnaround.
Reported Results
For the third quarter ended September 30, 2026, Definitive Healthcare (DH) posted total revenue of $54.7 million, a decline of roughly 9% from $60.0 million in the same period a year ago. The figure landed within the company's guidance range of $54.0–$55.0 million.
Profitability, however, came in ahead of expectations. Adjusted EBITDA was $15.8 million, equating to a 29% margin, above the guided range of $13.5–$14.5 million. Adjusted net income was $8.8 million, or $0.06 per diluted share, exceeding both the company's $0.04–$0.05 outlook and the $0.04 consensus estimate. Adjusted operating income was $12.8 million, down from $16.3 million a year earlier.
On a GAAP basis, the company's net loss narrowed to about $5.4 million, or $0.04 per share, from $17.8 million, or $0.14 per share, in the prior-year quarter. Adjusted gross margin was 81%, down modestly from 82% a year ago. Operating cash flow came in at $11.4 million, with unlevered free cash flow of $13.0 million, both lower than the comparable year-ago figures. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Sentiment heading into the report was cautious, reflecting a multi-quarter pattern of declining revenue offset by better-than-expected profitability. Definitive Healthcare's (DH) third-quarter results followed a familiar script: the top line continued to contract, but management once again outperformed on adjusted earnings and margin. The narrowing GAAP loss and above-guidance adjusted EBITDA are likely to be read positively, though persistent revenue declines and softer cash flow may temper enthusiasm. Investors will weigh the improved retention metrics and customer win-backs cited by management against the still-unresolved question of when organic growth will return, with the stock's reaction likely hinging on the company's updated fourth-quarter and full-year commentary.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should focus on whether Definitive Healthcare (DH) can stabilize its revenue base after several quarters of high-single-digit declines. Management has pointed to improving net dollar retention and customer win-backs as early signs of a turnaround, but converting those signals into sustained top-line growth remains the central challenge.
Margin management will stay in focus. The company has repeatedly raised its profitability guidance even as revenue softens, a trend worth monitoring to see whether cost discipline can continue offsetting lower sales without sacrificing investment in product and AI capabilities.
Key metrics to watch in the coming quarters include remaining performance obligations and deferred revenue, which provide visibility into future subscription activity, as well as any shifts in contract duration. Professional services demand, which has been a source of volatility, and the pace of recovery in the life sciences segment will also be important indicators. Guidance updates around full-year revenue and adjusted EBITDA will help clarify whether the company is on track for its return to growth. From what I see, this remains the most important area to track.
Using AI Tools for Deeper Analysis
In my view, tools like Tickeron’s AI Screener can help investors quickly compare DH against peers in the healthcare technology space by filtering on fundamentals, technical patterns, and performance metrics. I find it useful for surfacing comparable setups without spending hours on manual research, especially when evaluating whether the recent earnings trends are unique to this name or part of a broader sector pattern.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DH's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for DH turned positive on October 19, 2026. Looking at past instances where DH's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on DH as a result. In 64 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +8.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where DH advanced for three days, in 191 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 121 of 164 cases where DH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
DH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.834) is normal, around the industry mean (4.886). P/E Ratio (-0.698) is within average values for comparable stocks, (13.782). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.437) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. DH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement